| 4.15 0.36 (9.5%) | 12-12 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.42 | 1-year : | 7.5 |
| Resists | First : | 5.5 | Second : | 6.42 |
| Pivot price | 4.42  |
|||
| Supports | First : | 3.27 | Second : | 1.89 |
| MAs | MA(5) : | 4.18 |
MA(20) : | 4.12 |
| MA(100) : | 2.66 |
MA(250) : | 0 | |
| MACD | MACD : | 0.4 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 31.6 |
D(3) : | 42.2 |
| RSI | RSI(14): 56.5 |
|||
| 52-week | High : | 5.59 | Low : | 1.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ANVS ] has closed above bottom band by 31.2%. Bollinger Bands are 57.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 18 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.24 - 4.26 | 4.26 - 4.28 |
| Low: | 3.64 - 3.67 | 3.67 - 3.7 |
| Close: | 4.11 - 4.15 | 4.15 - 4.19 |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Mon, 08 Dec 2025
Annovis Bio director Hoffman buys $193,794 in shares - Investing.com
Wed, 03 Dec 2025
Annovis Bio (NYSE: ANVS) to share buntanetap cognitive data in PD, AD at 2025 PSG meeting - Stock Titan
Mon, 24 Nov 2025
Annovis Announces Two Presentations at the CTAD 2025 Conference - GlobeNewswire
Fri, 21 Nov 2025
Annovis Bio director Hoffman buys $69.9k in ANVS stock - Investing.com
Mon, 17 Nov 2025
Annovis Bio Stock Jumps On Heels Of New Parkinson's Data - Annovis Bio (NYSE:ANVS) - Benzinga
Wed, 12 Nov 2025
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 15.2 (%) |
| Held by Institutions | 11.3 (%) |
| Shares Short | 1,310 (K) |
| Shares Short P.Month | 1,300 (K) |
| EPS | -1.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.64 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -105.9 % |
| Return on Equity (ttm) | -246.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -2.91 |
| PEG Ratio | 0 |
| Price to Book value | 6.38 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|